The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy.

This document together with the guidance published on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (NICE interventional procedure guidance 257) replaces previous guidance on pancreatic islet cell transplantation.


Patients with chronic pancreatitis or some pancreatic tumours may require the surgical removal of all, or part, of their pancreas. As the pancreas is responsible for insulin production, surgical removal of the pancreas causes these patients to develop insulin-dependent diabetes.

Autologous pancreatic islet cell transplantation involves the removal of parts of the patient's own pancreas (the islet cells, which are responsible for insulin production), after the pancreas has been removed. These cells are then inserted into the patient's liver to restart insulin production within the body.

Coding and clinical classification codes for this guidance

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. 

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.